GO:0034185 apolipoprotein binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0034185 apolipoprotein binding is a molecular function defined as binding to an apolipoprotein, the protein component of a lipoprotein complex.
• Apolipoproteins such as APOE, APOA1, APOB, APOM, APOL9, and APOA(a) mediate lipid transport, receptor recognition, and vascular matrix interactions [1,2,6,8].
• Apolipoprotein binding is central to atherosclerosis, Alzheimer's disease, and lipoprotein metabolism because it controls particle clearance and cellular uptake [1,7].
• TREM2 binds APOE and CLU/APOJ, linking apolipoprotein binding to microglial amyloid-beta uptake in neurodegeneration.
• The receptor-binding domain of APOE has been mapped to specific fragments, making it a tractable target for point-mutation and knock-in studies [4,5].
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal testing of apolipoprotein binding in disease-relevant cell types.
Description
GO:0034185 apolipoprotein binding is a molecular function that describes the binding of a protein or other molecule to an apolipoprotein, the protein component of a lipoprotein complex. Apolipoproteins are amphipathic proteins that associate with lipids to form lipoproteins, and they serve as structural scaffolds, enzyme cofactors, and receptor ligands [1,2]. Because apolipoproteins control how lipid particles are assembled, remodeled, and cleared, the binding events captured by GO:0034185 are central to lipid transport and cardiovascular biology. Researchers study this term to understand how apolipoproteins interact with receptors, proteoglycans, and other proteins, and how those interactions influence disease. For example, the receptor-binding domain of human apolipoprotein E has been dissected using synthetic fragments, revealing which regions mediate binding to the LDL receptor [4,5]. Similarly, apolipoprotein(a) binds to the protein core of proteoglycans and other vascular matrix components through its C-terminal domain, a process implicated in atherosclerosis. In the brain, TREM2 binds apolipoproteins including APOE and CLU/APOJ, facilitating microglial uptake of amyloid-beta. These examples show that apolipoprotein binding is not a single interaction but a broad functional category encompassing receptor binding, matrix binding, and immune-receptor engagement. Understanding GO:0034185 therefore requires integrating structural, biochemical, and cell-biological evidence across multiple apolipoprotein families.
apolipoprotein binding At A Glance
| GO ID | GO:0034185 |
|---|---|
| GO term | apolipoprotein binding |
| Ontology | molecular_function |
| Synonym | None listed |
| Definition | Binding to an apolipoprotein, the protein component of a lipoprotein complex. |
| Major function | Mediates physical interaction with apolipoproteins, enabling lipoprotein recognition, cellular uptake, and matrix retention. |
| Representative apolipoproteins | APOE, APOA1, APOB, APOM, APOL9, APOA(a) |
| Disease relevance | Atherosclerosis, Alzheimer's disease, lipoprotein metabolism disorders |
| Research methods | Surface plasmon resonance, co-immunoprecipitation, CRISPR knockout, point mutation, knock-in, overexpression |
What Is GO:0034185?
According to the Gene Ontology, GO:0034185 apolipoprotein binding is defined as binding to an apolipoprotein, the protein component of a lipoprotein complex. In practical terms, this means the function is carried out by any protein or molecule that physically interacts with an apolipoprotein, whether that apolipoprotein is lipidated or lipid-free. The term is a molecular function, so it describes a binding activity rather than a biological process or cellular component. It does not specify the identity of the binding partner, the affinity, or the downstream consequence; those details come from experimental studies. For example, binding of APOE fragments to the LDL receptor and binding of TREM2 to APOE and CLU/APOJ are both instances of apolipoprotein binding. The QuickGO definition is intentionally broad to accommodate the many apolipoproteins and their diverse interaction partners.
Why Is apolipoprotein binding Important in Cell Biology?
Apolipoprotein binding is important because apolipoproteins are the protein determinants of lipoprotein fate. They direct where lipid particles go, which receptors they engage, and how they are cleared from circulation. Dysregulation of these interactions contributes to atherosclerotic disease, and apolipoproteins are actively studied as biomarkers and therapeutic targets. In the brain, apolipoprotein binding by immune receptors such as TREM2 controls amyloid-beta uptake, connecting this molecular function to Alzheimer's disease pathogenesis. The specificity of apolipoprotein binding also determines the receptor-binding domain of APOE, which has been mapped with fragment studies [4,5]. Because the function is so central, researchers need reliable models to test which residues, domains, and partners are required for binding. CRISPR-based cell models provide that causal resolution.
• Controls lipoprotein clearance and reverse cholesterol transport through receptor recognition.
• Underlies the receptor-binding domain of APOE, a key determinant of LDL receptor interaction [4,5].
• Mediates apolipoprotein(a) retention in the vascular matrix, contributing to atherosclerosis.
• Enables TREM2-dependent microglial uptake of amyloid-beta via APOE and CLU/APOJ binding.
• Regulates phospholipid and phosphatidylethanolamine interactions of apolipoproteins such as APOL9.
• Provides a mechanistic basis for dyslipidemia and cardiovascular risk assessment.
• Links apolipoprotein M biology to lipoprotein metabolism and inflammation.
• Offers a target for therapeutic modulation of lipoprotein particle fate.
• Supports biomarker development for neurodegenerative and cardiovascular disease [1,7].
• Enables functional annotation of variants in APOE, APOA1, APOB, and related genes.
What Happens During apolipoprotein binding?
Apolipoprotein recognition and initial contact
In simple terms: First, the binding partner recognizes and touches the apolipoprotein.
Apolipoprotein binding begins when a binding partner, such as a receptor, proteoglycan, or immune receptor, makes initial contact with an apolipoprotein. This contact depends on the surface properties of the apolipoprotein, including amphipathic helices that interact with lipids and with other proteins [1,3]. Synthetic apolipoprotein fragments have been used to show that phospholipid binding and protein-protein contact are separable features of apolipoprotein structure. The receptor-binding domain of human apolipoprotein E has been mapped using fragments, demonstrating that specific regions of APOE are responsible for binding to the LDL receptor. This step is therefore governed by the primary sequence and conformation of the apolipoprotein.
Domain-specific engagement
In simple terms: Different parts of the apolipoprotein do different jobs during binding.
Apolipoproteins are modular, and distinct domains mediate distinct binding events. In apolipoprotein(a), the C-terminal domain plays a dominant role in binding to the protein core of proteoglycans and other members of the vascular matrix. In APOE, the receptor-binding domain has been localized to specific fragments, and polymorphism in APOE affects this binding domain [4,5]. These domain-specific interactions explain why apolipoprotein binding is not a single uniform activity but a collection of structurally defined events. Researchers use fragment mapping and mutagenesis to assign binding functions to particular domains.
Lipoprotein particle context
In simple terms: Binding often happens while the apolipoprotein is part of a lipid particle.
Many apolipoprotein binding events occur in the context of a lipoprotein complex, where the apolipoprotein is associated with phospholipids, cholesterol, and triglycerides. The QuickGO definition explicitly refers to the apolipoprotein as the protein component of a lipoprotein complex. Phospholipid binding studies with synthetic apolipoprotein fragments show that lipid association and protein binding are coupled properties. Apolipoprotein M is another example of an apolipoprotein whose biology is tied to lipoprotein particles and their metabolism. Thus, the lipid environment can modulate apolipoprotein binding by altering apolipoprotein conformation and accessibility.
Cellular uptake and downstream signaling
In simple terms: After binding, the partner cell can take up the particle or trigger a response.
Apolipoprotein binding frequently leads to cellular uptake or signaling. TREM2 binds apolipoproteins including APOE and CLU/APOJ and thereby facilitates uptake of amyloid-beta by microglia. This demonstrates that apolipoprotein binding can be an upstream step in a phagocytic or endocytic pathway. In the vasculature, apolipoprotein binding to matrix components such as proteoglycans can retain lipoproteins in the arterial wall, a process linked to atherosclerotic disease [1,6]. The downstream consequence therefore depends on the identity of the binding partner and the cellular context.
Regulation of binding affinity
In simple terms: The strength and specificity of binding can be tuned by the cell and the environment.
Apolipoprotein binding is regulated by factors including apolipoprotein polymorphism, lipid composition, and the presence of competing ligands. APOE polymorphism affects the receptor-binding domain, altering how APOE interacts with receptors. Apolipoprotein M biology is also influenced by its association with lipoproteins and its interaction partners. Mouse apolipoprotein L9 is a phosphatidylethanolamine-binding protein, illustrating that apolipoproteins can have specific lipid-binding preferences that influence their protein interactions. These regulatory layers mean that binding affinity measured in vitro may not fully predict binding in a cellular or physiological context.
Key Genes Involved in GO:0034185 apolipoprotein binding
The following genes encode apolipoproteins or apolipoprotein-binding proteins that are directly relevant to GO:0034185 apolipoprotein binding.
| Gene | Major Role | Research Relevance |
|---|---|---|
| APOE | Apolipoprotein E; receptor-binding domain mediates lipoprotein clearance | Central to atherosclerosis and Alzheimer's disease; target for point-mutation and knock-in studies [4,5,7] |
| APOA1 | Major HDL apolipoprotein; structural and functional component of HDL | Studied in reverse cholesterol transport and cardiovascular disease |
| APOB | Core apolipoprotein of LDL and VLDL; ligand for LDL receptor | Key marker of atherosclerotic risk and lipoprotein metabolism |
| APOM | Apolipoprotein M; associates with HDL and modulates lipoprotein metabolism | Linked to inflammation and lipoprotein biology |
| APOL9 | Mouse apolipoprotein L9; phosphatidylethanolamine-binding protein | Model for apolipoprotein-lipid binding specificity |
| APOA(a) | Apolipoprotein(a); C-terminal domain binds vascular matrix proteoglycans | Implicated in atherosclerosis and matrix retention |
| TREM2 | Immune receptor that binds APOE and CLU/APOJ | Mediates microglial amyloid-beta uptake in neurodegeneration |
| CLU/APOJ | Clusterin/apolipoprotein J; binds TREM2 | Involved in amyloid-beta clearance and Alzheimer's disease |
| LDLR | LDL receptor; binds APOE and APOB | Classic receptor for apolipoprotein binding studies |
| LRP1 | LDL receptor-related protein 1; binds multiple apolipoproteins | Endocytic receptor in vascular and neuronal cells |
| ABCA1 | Cholesterol efflux transporter; lipidates APOA1 | Required for HDL biogenesis and apolipoprotein function |
| ABCG1 | Cholesterol efflux transporter; interacts with HDL apolipoproteins | Studied in macrophage cholesterol efflux |
| CETP | Cholesteryl ester transfer protein; interacts with lipoproteins | Modulates lipoprotein composition and apolipoprotein binding |
| PLTP | Phospholipid transfer protein; remodels lipoproteins | Affects apolipoprotein conformation and binding |
| LCAT | Lecithin-cholesterol acyltransferase; activated by APOA1 | Enzyme cofactor function of apolipoproteins |
| SAA | Serum amyloid A; apolipoprotein associated with HDL | Acute-phase apolipoprotein with binding functions |
| PON1 | Paraoxonase 1; associates with HDL and APOA1 | Modulates lipoprotein oxidation and binding |
How Is apolipoprotein binding Regulated?
Apolipoprotein binding is regulated at multiple levels. Genetic polymorphism in APOE alters the receptor-binding domain and therefore changes binding specificity. The lipid environment modulates apolipoprotein conformation; phospholipid binding studies with synthetic fragments show that lipid association can change how apolipoproteins interact with other molecules. Apolipoprotein M is regulated in the context of lipoprotein particles and their remodeling. In the brain, TREM2-mediated apolipoprotein binding is part of an immune-receptor pathway that can be modulated by disease-associated variants. Additionally, the C-terminal domain of apolipoprotein(a) determines its binding to vascular matrix components, and this interaction can be influenced by the composition of the matrix. Together, these layers of regulation mean that apolipoprotein binding is context-dependent and can be tuned by genetic, lipid, and environmental factors.
apolipoprotein binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| APOE | Alzheimer's disease; atherosclerosis | Knock-in of APOE isoforms in iPSC-derived microglia or hepatocytes |
| APOA(a) | Atherosclerosis; vascular matrix retention | Knockout of APOA(a) C-terminal domain in hepatic cell lines |
| TREM2 | Alzheimer's disease; microglial amyloid clearance | Knockout and point-mutation in iPSC-derived microglia |
| APOM | Lipoprotein metabolism; inflammation | Overexpression and knockout in hepatocyte models |
| APOL9 | Phosphatidylethanolamine binding; lipid metabolism | Knockout in mouse or cell-line models |
Atherosclerotic cardiovascular disease
Apolipoproteins are central to vascular biology and atherosclerotic disease. Apolipoprotein binding to receptors and matrix components determines whether lipoproteins are cleared or retained in the arterial wall. Apolipoprotein(a) binds to the protein core of proteoglycans and other vascular matrix members through its C-terminal domain, a process that contributes to lipoprotein retention and plaque formation. APOE and APOB are ligands for the LDL receptor, and their binding domains have been characterized in detail [4,5]. Dysregulation of these interactions is a major driver of dyslipidemia and atherosclerosis.
Alzheimer's disease and neurodegeneration
In the brain, apolipoprotein binding is linked to amyloid-beta clearance. TREM2 binds apolipoproteins including APOE and CLU/APOJ and thereby facilitates uptake of amyloid-beta by microglia. This places apolipoprotein binding directly in the pathway of microglial amyloid clearance, a process that is impaired in Alzheimer's disease. APOE polymorphism also affects the receptor-binding domain, which may influence neuronal and glial handling of lipoproteins. These findings make GO:0034185 a relevant function for neurodegeneration research.
Lipoprotein metabolism disorders
Apolipoprotein M is an apolipoprotein whose biology is tied to lipoprotein metabolism and inflammation. Mouse apolipoprotein L9 is a phosphatidylethanolamine-binding protein, showing that apolipoproteins can have specific lipid-binding properties that affect their function. Disorders of lipoprotein metabolism often involve altered apolipoprotein binding to receptors, enzymes, or transfer proteins. Studying these interactions helps explain variability in lipid levels and disease risk.
From apolipoprotein binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is APOE required for TREM2-mediated amyloid-beta uptake? | APOE knockout in iPSC-derived microglia or microglial cell lines |
| Which APOE residues mediate LDL receptor binding? | Point mutation of the receptor-binding domain followed by binding assays |
| Does a disease-associated APOE variant alter apolipoprotein binding? | Knock-in of the variant allele in isogenic cell lines |
| Where does APOA(a) bind in the vascular matrix? | Tagged knock-in of APOA(a) C-terminal domain with imaging |
| Does APOM overexpression change lipoprotein binding? | Overexpression of APOM in hepatocyte cell lines |
| Can APOL9 lipid-binding specificity be redirected? | Point mutation of the phosphatidylethanolamine-binding site |
How to Study the apolipoprotein binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Surface plasmon resonance | Binding affinity and kinetics | Measure APOE-receptor interactions |
| Co-immunoprecipitation | Physical interaction in cell lysates | Identify TREM2-APOE complexes |
| Phospholipid binding assay | Lipid association of apolipoprotein fragments | Map APOL9 and APOA1 lipid-binding regions |
| CRISPR knockout | Loss-of-function effect on binding | Test requirement of APOE in amyloid uptake |
| Point mutation | Residue-specific contribution to binding | Map APOE receptor-binding domain |
| Knock-in | Effect of disease variant on binding | Model APOE isoform-specific binding |
| Overexpression | Gain-of-function effect on binding | Test APOM and APOL9 binding capacity |
Binding assays for apolipoprotein interactions
Direct binding assays such as surface plasmon resonance, isothermal titration calorimetry, and enzyme-linked binding assays are used to measure affinity and specificity between apolipoproteins and their partners. Synthetic apolipoprotein fragments have been used in phospholipid binding studies to dissect which regions mediate lipid and protein interactions. Receptor-binding domain mapping of APOE fragments is a classic example of this approach. These methods provide quantitative parameters that can be compared across wild-type and mutant apolipoproteins.
Co-immunoprecipitation and proximity labeling
Co-immunoprecipitation and proximity labeling can identify endogenous apolipoprotein binding partners in cells and tissues. TREM2 binding to APOE and CLU/APOJ was demonstrated using biochemical interaction methods. These approaches are useful for discovering novel partners and for confirming whether a candidate interaction occurs in a physiological context. When combined with CRISPR knockout of the apolipoprotein gene, they can establish whether the interaction is direct or indirect.
CRISPR-based perturbation and functional readouts
CRISPR knockout, point mutation, knock-in, and overexpression allow causal testing of apolipoprotein binding. For example, knocking out APOE or TREM2 can test whether amyloid-beta uptake depends on their interaction. Point mutations in the APOE receptor-binding domain can test which residues are required for LDL receptor binding [4,5]. These perturbations are typically combined with binding assays, uptake assays, or imaging to connect molecular function to cellular phenotype.
Imaging and localization studies
Fluorescence imaging and tagged knock-in approaches can visualize where apolipoprotein binding occurs in cells and tissues. Tagged APOA(a) can be used to track its C-terminal domain binding to vascular matrix components. Localization studies help distinguish surface binding from internalization and can reveal whether binding is altered by disease-associated variants. These methods are especially valuable when combined with quantitative binding data.
How CRISPR Can Be Used to Study GO:0034185 apolipoprotein binding
Knockout
CRISPR knockout of apolipoprotein genes or their binding partners is used to test whether a specific interaction is required for a cellular phenotype. For example, knocking out APOE or TREM2 can determine whether apolipoprotein binding is necessary for microglial amyloid-beta uptake. Knockout models are also useful for validating antibody specificity and for establishing baseline binding in the absence of the target protein.
Point Mutation
Point mutation is used to dissect which residues mediate apolipoprotein binding. The receptor-binding domain of human apolipoprotein E has been mapped using fragments, and point mutations can refine this map to individual residues [4,5]. Point-mutant cell lines are valuable for distinguishing binding defects from folding or secretion defects when combined with appropriate controls.
Knock-in
Knock-in of disease-associated variants allows researchers to test how specific alleles affect apolipoprotein binding in an isogenic background. APOE polymorphism is a classic example, where different isoforms alter the receptor-binding domain. Knock-in models can also be used to tag endogenous apolipoproteins for imaging or affinity purification, as with APOA(a) C-terminal domain studies.
Overexpression
Overexpression of apolipoproteins or their binding partners is used to test gain-of-function effects on binding and downstream phenotypes. Overexpression of APOM or APOL9 can reveal whether increased protein levels alter lipoprotein interactions [2,8]. Overexpression models are also useful for producing sufficient material for biochemical binding assays.
How EDITGENE Supports apolipoprotein binding Research
Researchers studying apolipoprotein binding-related genes often need to determine whether a candidate gene is causally involved in a binding event or whether it is merely correlated with a disease phenotype. This requires precise genetic perturbation in relevant cell types, combined with quantitative binding and functional readouts. EDITGENE provides the CRISPR tools and cell models needed to move from correlation to causation in apolipoprotein biology.
Contact EDITGENE today to design your custom CRISPR model for apolipoprotein binding research.
Frequently Asked Questions About apolipoprotein binding
What is GO:0034185 apolipoprotein binding?
GO:0034185 apolipoprotein binding is a Gene Ontology molecular function defined as binding to an apolipoprotein, the protein component of a lipoprotein complex.
What genes are involved in apolipoprotein binding?
Key genes include APOE, APOA1, APOB, APOM, APOL9, APOA(a), TREM2, and CLU/APOJ, among others [1,2,6,7,8].
Why is apolipoprotein binding important in disease?
It controls lipoprotein clearance, vascular matrix retention, and microglial amyloid-beta uptake, linking it to atherosclerosis and Alzheimer's disease [1,6,7].
How is apolipoprotein binding studied experimentally?
Common methods include surface plasmon resonance, co-immunoprecipitation, phospholipid binding assays, and CRISPR-based perturbation [3,5,7].
What is the receptor-binding domain of APOE?
The receptor-binding domain of human apolipoprotein E is the region that mediates binding to the LDL receptor, and it has been mapped using APOE fragments [4,5].
Does TREM2 bind apolipoproteins?
Yes, TREM2 binds apolipoproteins including APOE and CLU/APOJ and thereby facilitates uptake of amyloid-beta by microglia.
What is the role of apolipoprotein(a) in the vascular matrix?
The C-terminal domain of apolipoprotein(a) plays a dominant role in binding to the protein core of proteoglycans and other vascular matrix components.
What is apolipoprotein M?
Apolipoprotein M is an apolipoprotein associated with lipoproteins, and its biology is linked to lipoprotein metabolism and inflammation.
Is APOL9 a lipid-binding protein?
Mouse apolipoprotein L9 is a phosphatidylethanolamine-binding protein, indicating specificity for certain phospholipids.
How can CRISPR help study apolipoprotein binding?
CRISPR knockout, point mutation, knock-in, and overexpression allow causal testing of which genes and residues are required for apolipoprotein binding in relevant cell models [4,5,7].
Conclusion
GO:0034185 apolipoprotein binding is a broad but mechanistically rich molecular function that underlies lipoprotein recognition, cellular uptake, and vascular matrix retention. Its importance spans cardiovascular disease, neurodegeneration, and lipoprotein metabolism, with APOE, APOA(a), APOM, APOL9, TREM2, and CLU/APOJ as representative players [1,2,6,7,8]. Because binding is domain-specific and regulated by polymorphism and lipid context, precise genetic models are essential for causal inference [3,4,5]. CRISPR-based knockout, point-mutation, knock-in, and overexpression platforms provide the resolution needed to dissect these interactions and to translate them into therapeutic hypotheses.
References
- 1. Mehta A et al.. 2022. Apolipoproteins in vascular biology and atherosclerotic disease.. Nat Rev Cardiol 19(3):168-179 PMID: 34625741
- 2. Ren K et al.. 2015. Apolipoprotein M.. Clin Chim Acta 446:21-9 PMID: 25858547
- 3. Sparrow JT et al.. 1980. Phospholipid binding studies with synthetic apolipoprotein fragments.. Ann N Y Acad Sci 348:187-211 PMID: 6772077
- 4. Bekaert ED et al.. 1986. [Human apolipoprotein E: polymorphism and binding domain of the receptors].. Biochimie 68(5):629-37 PMID: 3015256
- 5. Innerarity TL et al.. 1983. The receptor-binding domain of human apolipoprotein E. Binding of apolipoprotein E fragments.. J Biol Chem 258(20):12341-7 PMID: 6313652
- 6. Scanu AM et al.. 1999. Dominant role of the C-terminal domain in the binding of apolipoprotein(a) to the protein core of proteoglycans and other members of the vascular matrix.. Trends Cardiovasc Med 9(7):196-200 PMID: 10881751
- 7. Yeh FL et al.. 2016. TREM2 Binds to Apolipoproteins, Including APOE and CLU/APOJ, and Thereby Facilitates Uptake of Amyloid-Beta by Microglia.. Neuron 91(2):328-40 PMID: 27477018
- 8. Arvind TA et al.. 2016. Mouse Apolipoprotein L9 is a phosphatidylethanolamine-binding protein.. Biochem Biophys Res Commun 479(4):636-642 PMID: 27697524
